Dark

AMGN
Amgen Inc
stock NASDAQ

At Close

Jul 21, 2026 3:59:57 PM EDT

366.15USD+0.544%(+1.98)2,860,293

366.05Bid 383.25Ask 17.20Spread

Pre-market

Jul 21, 2026 9:27:30 AM EDT

364.17USD0.000%(0.00)1,655

After-hours

Jul 21, 2026 4:24:30 PM EDT

366.24USD+0.025%(+0.09)1,070,516

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

04:51PM EST Amgen Reports In 8K Filing Co Entered Into Amendment No. 3 To Exclusive License & Collaboration Agreement With Novartis Benzinga

Jan 20, 2022

08:52AM EST Amgen's Lumakras Approved In Japan For Pretreated Lung Cancer Patients Benzinga

08:28AM EST The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug Benzinga

04:30AM EST LUMAKRAS(r) (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS PR Newswire

Jan 13, 2022

11:45AM EST BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398 Benzinga

11:45AM EST Amgen And AstraZeneca Announce Availability Of TEZSPIRE For Shipment To Wholesalers In US Benzinga

11:45AM EST Astrazeneca And Amgen Today Announced TEZSPIRE Is Now Available For Shipment To Wholesalers In The U.S. Benzinga

11:45AM EST Amgen And AstraZeneca Announce Availability Of TEZSPIRE For Shipment To Wholesalers In US Benzinga

07:24AM EST AstraZeneca (AZN.L, AZN) and Amgen, Inc. (AMGN) announced Thursday the availability of Tezspire (tezepelumab-ekko) for shipment to wholesalers in the US. RTTNews

07:02AM EST Amgen Says Tezspire Now Available In U.S. For Treatment Of Severe Asthma RTTNews

07:01AM EST TEZSPIRE(tm) (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE PR Newswire

Jan 11, 2022

09:54AM EST A Look Into Amgen's Price Over Earnings Benzinga

09:37AM EST Amgen (AMGN) said that it has reached a research collaboration with Arrakis Therapeutics to focus on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas. RTTNews

09:05AM EST UPDATE: Amgen To Pay Arrakis $75M For 5 Initial Programs Benzinga

09:05AM EST Amgen, Arrakis Therapeutics Report Multi-Target Collab To Identify Novel RNA Degrader Small Molecule Therapeutics Benzinga

09:03AM EST Amgen And Arrakis Therapeutics Collaborate To Identify Novel RNA Degrader Small Molecule Therapeutics RTTNews

09:01AM EST AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY PR Newswire

Jan 10, 2022

04:01PM EST AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA PR Newswire

07:25AM EST Europe Approves Amgen's KRAS-Targeted Lung Cancer Therapy Benzinga

05:28AM EST Amgen Announced on Sunday European Commission Approved Lumykras for Patients With KRAS G12C-mutated Advanced Non-small Cell Lung Cancer Benzinga

02:03AM EST Amgen Inc. (AMGN), said on Monday that the European Commission has granted conditional marketing authorization for Lumykras for patients with KRAS G12C-mutated advanced non-small cell lung cancer. RTTNews

12:08AM EST Amgen: EU Grants Conditional Marketing Authorization For LUMYKRAS For Patients With The KRAS G12C Mutated Advanced NSCLC RTTNews

12:00AM EST EUROPEAN COMMISSION APPROVES LUMYKRAS(r) (SOTORASIB) FOR PATIENTS WITH KRAS PR Newswire

Jan 9, 2022

05:24PM EST 2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again? Benzinga

Jan 6, 2022

04:01PM EST AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire

09:02AM EST AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH PR Newswire

09:02AM EST Amgen, Generate Bio Report Multi-Target, Multi-Modality Research Collab; Amgen To Pay $50M In Upfront Funding With Potential For Total Transaction Value Of $1.9B Including Royalties Benzinga

Jan 5, 2022

11:03AM EST Expert Ratings For Amgen Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 Benzinga

07:20AM EST B of A Securities Downgrades Amgen to Neutral, Lowers Price Target to $255 Benzinga

Jan 4, 2022

08:11AM EST The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives Benzinga

Dec 23, 2021

04:00PM EST AMGEN TO PRESENT AT THE GOLDMAN SACHS 14TH ANNUAL HEALTHCARE CEOS UNSCRIPTED PR Newswire

Dec 21, 2021

10:39AM EST Analyst Ratings For Amgen Benzinga

10:33AM EST Expert Ratings For Amgen Benzinga

09:05AM EST Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level Benzinga

07:04AM EST RBC Capital Maintains Sector Perform on Amgen, Raises Price Target to $218 Benzinga

Dec 20, 2021

04:38PM EST FDA Approves Otezla For Treatment Of Adult Patients With Plaque Psoriasis RTTNews

04:25PM EST Amgen Reports FDA Approval Of Otezla For Treatment Of Adult Patients With Plaque Psoriasis, Regardless Of Severity Level Benzinga

04:25PM EST FDA APPROVES OTEZLA(r) (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PR Newswire

02:43PM EST Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut Benzinga

05:20AM EST AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma Benzinga

04:44AM EST AstraZeneca Announced Tezspire Approved in the US for Severe Asthma Benzinga

02:33AM EST AstraZeneca (AZN.L, AZN) and Amgen's Tezspire or tezepelumab-ekko has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma. RTTNews

Dec 19, 2021

12:54PM EST The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week Benzinga

Dec 17, 2021

04:31PM EST Amgen Reports FDA Approval Of It, AstraZeneca's Tezspire For Add-On Maintenance Treatment Of Adult, Pediatric Patients With Severe Asthma Benzinga

04:30PM EST FDA APPROVES TEZSPIRE(tm) (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA PR Newswire

Dec 16, 2021

11:47AM EST Check Out What Whales Are Doing With AMGN Benzinga

Dec 9, 2021

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:47PM EST Wells Fargo Initiates Coverage On Amgen with Equal-Weight Rating, Announces Price Target of $210 Benzinga

Dec 6, 2021

04:03PM EST Amgen To Present At ASH 2021 Dec. 11-14 Benzinga

04:00PM EST Amgen Announces New Data Being Presented At ASH 2021 PR Newswire

11:13AM EST What 8 Analyst Ratings Have To Say About Amgen Benzinga

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 Benzinga

07:08AM EST Goldman Sachs Initiates Coverage On Amgen with Buy Rating, Announces Price Target of $258 Benzinga

06:05AM EST A Peek Into The Markets: US Stock Futures Mostly Higher; Crude Oil Up 2% Benzinga

Dec 3, 2021

04:06PM EST Amgen Inc. (AMGN) Declares $ 1.94 Dividend for Q1 22, Record Date 2/15/2022 RTTNews

04:05PM EST Amgen Declares Quarterly Dividend Of $1.94/share, Payable March 8/ Record Feb. 15 RTTNews

04:00PM EST Amgen Announces 10% Increase In 2022 First Quarter Dividend PR Newswire

Dec 2, 2021

12:02PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

07:51AM EST The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance Benzinga

06:52AM EST Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma Benzinga

06:21AM EST Amgen's Otezla Meets Primary Goal In Late-Stage Genital Psoriasis Study Benzinga

Dec 1, 2021

10:36PM EST Amgen : FDA Approves Kyprolis Combination Regimen For RTTNews

04:02PM EST Amgen Announces Top-Line Results From Otezla Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis; Study Showed Statistically Significant Improvement In Primary Endpoint, Met All Secondary Endpoints Benzinga

04:00PM EST Amgen Announces Positive Top-Line Results From Otezla(r) (apremilast) Phase 3 PR Newswire

01:29PM EST FASPRO(r) (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse PR Newswire

11:57AM EST J&J Shares At New Session High, Up 2.2%; FDA Has Approved Co., Amgen's Dexamethasone For Multiple Myeloma; Amgen Shares Quiet Benzinga

Nov 30, 2021

04:03PM EST Price Over Earnings Overview: Amgen Benzinga

04:02PM EST Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis Benzinga

Nov 29, 2021

04:01PM EST Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year PR Newswire

Nov 24, 2021

04:22PM EST Amgen To Present At The 2021 Evercore ISI Healthcare Conference Nov. 30 Benzinga

04:13PM EST Amgen CFO To Present At Piper Sandler Healthcare Conference Dec. 1, 2021 At 1 p.m. EST Benzinga

04:05PM EST Amgen To Present At The 2021 Evercore ISI Healthcare Conference PR Newswire

04:00PM EST Amgen To Present At The 2021 Piper Sandler Healthcare Conference PR Newswire

Nov 22, 2021

07:30AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:14AM EST Mizuho Maintains Neutral on Amgen, Lowers Price Target to $194 Benzinga

Nov 19, 2021

12:01PM EST Analyst Ratings For Amgen Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:32AM EST BMO Capital Initiates Coverage On Amgen with Market Perform Rating, Announces Price Target of $228 Benzinga

Nov 17, 2021

09:03AM EST Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT PR Newswire

Nov 12, 2021

07:57AM EST Amgen : Lumakras Gets Positive CHMP Opinion For Advanced RTTNews

07:36AM EST Amgen Reports Positive European Medicines Agency Committee For Medicinal Products For Human Use For LUMYKRAS For Patients With KRAS G12C-Mutation Benzinga

07:33AM EST Amgen :LUMYKRAS Gets Positive CHMP Opinion For KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer RTTNews

07:31AM EST LUMYKRAS(r) (sotorasib) Receives Positive Opinion From EMA CHMP For Patients PR Newswire

Nov 10, 2021

04:01PM EST Amgen To Present At The 2021 Annual Cowen IO Summit PR Newswire

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:10AM EST Amgen Highlights First And Only Randomized, Double-blind, Head-To-head Study Comparing Aimovig (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia Benzinga

Nov 8, 2021

04:09PM EST Aimovig(r) (erenumab-aooe), An Anti-CGRP Pathway Therapy, To Topiramate Published In Cephalalgia PR Newswire

Nov 5, 2021

04:01PM EDT Amgen Highlights Commencement Of Construction On New Biomanufacturing Plant In Central Ohio Benzinga

04:01PM EDT Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio PR Newswire

Nov 3, 2021

12:30PM EDT Where Amgen Stands With Analysts Benzinga

09:20AM EDT RBC Capital Maintains Sector Perform on Amgen, Lowers Price Target to $216 Benzinga

09:17AM EDT Barclays Maintains Equal-Weight on Amgen, Lowers Price Target to $228 Benzinga

09:15AM EDT Amgen Q3 Earnings Saved By Higher Volumes Despite Pricing Pressure On Some Drugs Benzinga

09:15AM EDT SVB Leerink Maintains Market Perform on Amgen, Lowers Price Target to $216 Benzinga

09:11AM EDT A Peek Into The Markets: US Stock Futures Mixed; All Eyes On Fed Decision Benzinga

Nov 2, 2021

05:34PM EDT Amgen: Q3 Earnings Insights Benzinga

04:30PM EDT Amgen Posts Promising FY Outlook After Narrower Profit In Q3 RTTNews

04:08PM EDT Amgen Inc. (AMGN) reported earnings for third quarter that declined from the same period last year. RTTNews

04:06PM EDT Amgen Q3 EPS $3.31 Vs. $3.43 Year Ago RTTNews

04:06PM EDT Amgen Sees FY21 Adj. EPS $16.50-$17.10 vs $16.43 Est., Sees FY21 Sales $25.8B-$26.2B vs $26.01B Est. Benzinga

04:04PM EDT Amgen Q3 Adj. EPS $4.67 Beats $4.27 Estimate, Sales $6.70B Beat $6.68B Estimate Benzinga

04:02PM EDT Amgen Reports Third Quarter 2021 Financial Results PR Newswire

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. GlobeNewswire Inc

Nov 1, 2021

10:56AM EDT Amgen's Earnings Outlook Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

04:01PM EDT Amgen Announces Webcast Of 2021 Third Quarter Financial Results PR Newswire

Oct 26, 2021

04:00PM EDT Fortune and Great Place to Work(r) Name Amgen One of the World's Best PR Newswire

Oct 21, 2021

04:05PM EDT Amgen Inc. (AMGN) Declares $ 1.76 Dividend for Q4 21, Record Date 11/16/2021 RTTNews

04:03PM EDT Amgen Declares Q4 Dividend Of $1.76/share, Payable Dec. 8/ Record Nov. 16 RTTNews

04:00PM EDT Amgen Announces 2021 Fourth Quarter Dividend PR Newswire

12:12PM EDT Economic Reports Reflect Labor Shortages and Moderate Economic Growth Benzinga

12:10PM EDT AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial Benzinga

Oct 19, 2021

09:21AM EDT Amgen Completes Acquisition Of Teneobio RTTNews

09:17AM EDT Amgen Successfully Completes Acquisition Of Teneobio, Inc. PR Newswire

Oct 12, 2021

12:31PM EDT Expert Ratings For Amgen Benzinga

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

08:05AM EDT Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $235 Benzinga

Oct 7, 2021

12:51PM EDT Amgen Highlights Lumakras Combination Data From Solid Tumor Trials Benzinga

11:00AM EDT Amgen (AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of Lumakras (sotorasib) in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers. RTTNews

09:05AM EDT Amgen Announces LUMAKRAS Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers RTTNews

09:05AM EDT CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021 PR Newswire

09:05AM EDT Amgen Reports LUMAKRAS Combed Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021 Conference Benzinga

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

07:27AM EDT Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases Benzinga

06:54AM EDT Amgen, Neumora Collaborate To Advance Neuroscience RTTNews

06:34AM EDT Amgen, Neumora Therapeutics Collaborate To Advance Neuroscience Discovery, Development And Commercialization RTTNews

06:33AM EDT Amgen And Neumora Therapeutics Announce Strategic R&D Collaboration To Accelerate Novel Precision Therapies For Brain Diseases Benzinga

06:30AM EDT Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to PR Newswire

Oct 4, 2021

04:01PM EDT Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment Benzinga

04:01PM EDT Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence PR Newswire

Oct 3, 2021

10:48AM EDT Amgen Reported a Stake of 2.7M Shares in Jasper Therapeutics in a 13G Filing on Friday Benzinga

Oct 2, 2021

06:11AM EDT Amgen And Kyowa Kirin Present Positive Data From Phase 2 Study Of AMG 451/KHK4083 At EADV Congress RTTNews

06:00AM EDT AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress PR Newswire

Sep 29, 2021

05:00PM EDT Amgen To Webcast Investor Call At EADV 2021 PR Newswire

Sep 27, 2021

07:32AM EDT Amgen's Repatha Scores FDA Nod For Pediatric Patients Over 10 Years With Inherited Heart Disease Benzinga

05:53AM EDT Acceleron In Advanced $11B Buyout Talks: Bloomberg Benzinga

Sep 24, 2021

08:12PM EDT FDA Approves Repatha(r) (evolocumab) In Pediatric Patients Age 10 And Older PR Newswire

Sep 23, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

06:25AM EDT Daiwa Capital Downgrades Amgen to Neutral, Announces $220 Price Target Benzinga

Sep 22, 2021

04:00PM EDT Amgen To Present At The 2021 Cantor Global Healthcare Conference PR Newswire

04:00PM EDT Amgen To Present At The 2021 Cantor Global Healthcare Conference Sept. 27 Benzinga

09:00AM EDT Amgen Releases 8th Edition of Biosimilar Trends Report PR Newswire

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 20, 2021

07:53PM EDT Amgen Wins Patent Case On Otezla RTTNews

07:03PM EDT Amgen Wins Patent Case on Otezla(r) (apremilast) PR Newswire

07:16AM EDT Verastem Oncology,Amgen Partner To Evaluate VS-6766 In With LUMAKRASTM In Patients With KRAS G12C-Mutant NSCLC RTTNews

07:02AM EDT Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer Benzinga

Sep 17, 2021

11:26AM EDT UPDATE: SVB Leerink On Amgen: Firm Notes Encouraging Responses In Sotorasib Nave Subjects Given Overall Response Rate At 33% With Many Patients Remaining On Combination Treatment After Median Of 10.3 Weeks; Expects Phase 3 Trial To Start In 2H21 Benzinga

11:25AM EDT SVB Leerink Maintains Market Perform Rating On Amgen Inc. With $234 Price Target Benzinga

Sep 16, 2021

08:09AM EDT Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer Benzinga

06:04AM EDT Amgen (AMGN) announced Thursday that combining LUMAKRAS (sotorasib) with Vectibix (panitumumab) demonstrated encouraging efficacy and safety in patients with KRAS G12C-Mutated colorectal cancer or CRC. RTTNews

04:39AM EDT Amgen Says LUMAKRAS With Vectibix Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated CRC RTTNews

04:30AM EDT Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer PR Newswire

Sep 14, 2021

04:00PM EDT Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will PR Newswire

04:00PM EDT Amgen, The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA Benzinga

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

07:47AM EDT Zai Lab Reports Breakthrough Therapy Designation For RTTNews

07:11AM EDT Health Canada Approves Lumakras For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Benzinga

Sep 13, 2021

04:15PM EDT Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare PR Newswire

04:00PM EDT Amgen To Webcast Investor Call At ESMO 2021 PR Newswire

09:02AM EDT Amgen To Showcase Data From Inflammation Portfolio At EADV Virtual Congress 2021; Take Place Virtually Sept. 29 - Oct. 2 RTTNews

09:02AM EDT Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress PR Newswire

Sep 9, 2021

05:00PM EDT Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference PR Newswire

07:19AM EDT Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients Benzinga

Sep 8, 2021

04:01PM EDT Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21 Benzinga

10:43AM EDT Downgrades On Economy And Pandemic Pharmaceuticals Benzinga

Sep 7, 2021

11:29AM EDT Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 Benzinga

06:08AM EDT Morgan Stanley Downgrades Amgen to Equal-Weight, Lowers Price Target to $251 Benzinga

Sep 5, 2021

10:57AM EDT Amgen (AMGN) said new data from the pivotal NAVIGATOR Phase 3 trial demonstrated that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps. RTTNews

07:15AM EDT New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With PR Newswire

Sep 3, 2021

04:00PM EDT Amgen to Present at the 16th Annual Citi BioPharma Conference PR Newswire

Aug 27, 2021

12:11PM EDT Amgen's Repatha Improves Plaque Stability In Heart Patients Benzinga

04:30AM EDT New Data At ESC Congress 2021 Shows Repatha(r) (evolocumab) Improves Features PR Newswire

Aug 11, 2021

07:55AM EDT WHO Says Solidarity Clinical Trial Enters New Phase With Three New Candidate Drugs For Treating COVID-19; Artesunate, Imatinib And Infliximab Were Selected By An Independent Expert Panel For Potential In Reducing The Risk Of Death In Hospitalized Patients Benzinga

Aug 4, 2021

02:44PM EDT Amgen Stops Phase 1 For One BiTE Molecule While Resuming Dosing For Another, Plans Second Drug Substance Plant Benzinga

07:36AM EDT SVB Leerink Maintains Market Perform on Amgen, Lowers Price Target to $234 Benzinga

06:50AM EDT Amgen Q2 Profit Falls On Five Prime Acquisition Related Write-off, Disputes IRS Claim On Owing $3.6B In Taxes Benzinga

Aug 3, 2021

04:21PM EDT Recap: Amgen Q2 Earnings Benzinga

04:08PM EDT Amgen Inc. (AMGN) reported earnings for second quarter that decreased from the same period last year. RTTNews

04:03PM EDT Amgen Q2 EPS $0.81 Vs. $3.05 Year Ago RTTNews

04:03PM EDT Amgen Reaffirms FY21 Guidance; Sees Sales $25.8B-$26.6B vs $26.04B Est., Sees Adj. EPS $16-$17 vs $16.34 Est. Benzinga

04:02PM EDT Amgen Q2 Adj. EPS $4.38 Beats $4.06 Estimate, Sales $6.50B Beat $6.43B Estimate Benzinga

04:02PM EDT Amgen Reports Second Quarter 2021 Financial Results PR Newswire

01:35PM EDT Amgen Announces Plans To Build Second New Manufacturing Facility In U.S.; Says Plans To Build New Multi-Product Drug Substance Manufacturing Facility In Holly Springs Benzinga

10:27AM EDT Another Big Earnings Week Ahead Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 1, 2021

12:58PM EDT Carter Worth And Mike Khouw's Amgen Trade Benzinga

Jul 30, 2021

04:04PM EDT Amgen Declares Quarterly Dividend Of $1.76/share, Payable Sept. 8/ Record Aug. 17 RTTNews

04:03PM EDT Amgen Inc. (AMGN) Declares $ 1.76 Dividend for Q3 21, Record Date 8/17/2021 RTTNews

04:00PM EDT Amgen Announces 2021 Third Quarter Dividend PR Newswire

Jul 29, 2021

07:42PM EDT Amgen Appoints Omar Ishrak To Board Of Directors RTTNews

04:00PM EDT Amgen Announces Webcast Of 2021 Second Quarter Financial Results PR Newswire

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

06:55AM EDT Amgen Buys Antibody Player Focused On PSMA In $2.5B Deal Benzinga

Jul 27, 2021

06:37PM EDT Amgen Inc. (AMGN) Tuesday said it has agreed to buy Teneobio, a privately acquired company, for $900 million. RTTNews

04:22PM EDT Amgen Announced It Has Entered An Agreement To Acquire Teneobio For A $900M Up-Front Cash Payment As Well As Contingent Milestone Payments To Teneobio Equity Holders Potentially Worth Up To $1.6B Benzinga

04:21PM EDT Amgen To Acquire Privately Held Teneobio For $900 Mln In Cash RTTNews

04:20PM EDT Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future PR Newswire

Jul 19, 2021

02:32PM EDT Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data Benzinga

11:01AM EDT Amgen's deCODE Subsidiary Highlights New Paper Published In Nature Genetics On Inheritance, Fetal Growth Benzinga

Jul 16, 2021

02:50PM EDT Where Amgen Stands With Analysts Benzinga

08:27AM EDT Morgan Stanley Maintains Overweight on Amgen, Raises Price Target to $280 Benzinga

Jul 15, 2021

12:19PM EDT FDA Rebukes Amgen Over Misleading Branding Of Neulasta Benzinga

Jul 14, 2021

03:38PM EDT Amgen Shares Quiet, FDA Notifies Co. Of Misbranding Of Biological Product, Neulasta, Due To False Or Misleading Promotional Communications About Product's Benefit Benzinga

03:38PM EDT UPDATE: FDA Says Determined Claims, Presentations By Amgen For Neulasta Are Not Supported Due To Multiple Limitations Of Study's Design, Analytic Strategy Benzinga

03:37PM EDT UPDATE: FDA Requests Amgen Cease Any Violations Of Federal Food, Drug, Cosmetic Act Benzinga

03:36PM EDT Amgen Shares Quiet, FDA Notifies Co. Of Misbranding Of Biological Product, Neulasta, Due To False Or Misleading Promotional Communications About Product's Benefit Benzinga

08:05AM EDT Amgen And The International Federation of Psoriasis Associations Launch UPLIFT PR Newswire

Jul 13, 2021

01:03PM EDT Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

06:16AM EDT BeiGene-Amgen's Kyprolis Gets Approval In China For Pre-Treated Multiple Myeloma Patients Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

07:22AM EDT How Does Amgen's Debt Look? Benzinga

07:01AM EDT Amgen - AstraZeneca's Asthma Candidate Under Priority Review With FDA Benzinga

02:28AM EDT Amgen (AMGN) said that the U.S. Food and Drug Administration has accepted a Biologics License Application and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. RTTNews

02:04AM EDT Amgen : Tezepelumab Granted Priority Review By FDA RTTNews

02:02AM EDT Tezepelumab Granted Priority Review By U.S. FDA PR Newswire

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jul 1, 2021

05:06PM EDT Labcorp Launches Companion Diagnostic For Amgen's Newly-Approved Lung Cancer Therapy Benzinga

Jun 29, 2021

03:01PM EDT Amgen Pumps $365M Into New Ohio Facility Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

06:05AM EDT Amgen (AMGN) announced Wednesday that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig (erenumab) for the suppression of onset of migraine attacks in adults. RTTNews

05:42AM EDT Amgen Announced Approval Of Aimovig In Japan For The Suppression Of Onset Of Migraine Attacks In Adults Benzinga

04:01AM EDT Amgen Announces Approval Of Aimovig In Japan For Suppression Of Onset Of Migraine Attacks In Adults RTTNews

04:01AM EDT Amgen Announces Approval Of Aimovig(r) (Erenumab) In Japan For The Suppression PR Newswire

Jun 18, 2021

05:00AM EDT deCODE genetics: Predicting the probability of death PR Newswire

Jun 15, 2021

08:01AM EDT Acclaimed Makeup Artist Allan Avendao Opens Up About Personal Skin Condition: PR Newswire

Jun 7, 2021

11:50AM EDT Expert Ratings for Amgen Benzinga

10:25AM EDT SVB Leerink Maintains Market Perform on Amgen, Raises Price Target to $238 Benzinga

10:04AM EDT Price Over Earnings Overview: Amgen Benzinga

09:33AM EDT Amgen's Sotorasib is First KRAS Inhibitor to Show Overall Survival Benefit in Lung Cancer With KRAS Mutations Benzinga

08:49AM EDT What Does Amgen's Debt Look Like? Benzinga

08:05AM EDT Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $277 Benzinga

Jun 4, 2021

05:00PM EDT Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire

04:01PM EDT Amgen Says Results From Phase 2 CodeBreaK 100 Show LUMAKRAS Is 'First And Only KRAS G12C Inhibitor With Overall Survival Data' Benzinga

04:00PM EDT Results From Phase 2 CodeBreaK 100 Show LUMAKRAS(tm) (sotorasib) Is The First PR Newswire

10:39AM EDT Amgen's Stomach Cancer Drug Acquired in Five Prime Buyout Extends Patients' Lives, Mid-Stage Study Shows Benzinga

10:22AM EDT Amgen, Inc. (AMGN) announced on Friday updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial. The trial evaluated bemarituzumab plus chemotherapy (mFOLFOX6) versus chemotherapy alone in patients with FGFR2b-positive, HER2-negative frontline advanced gastric or gastroesophageal junction cancers (GEJ). RTTNews

09:03AM EDT Amgen Announces Updated Results For Bemarituzumab In Combination With Chemotherapy From Phase 2 FIGHT Trial RTTNews

09:01AM EDT Amgen Offers Updated Results For Bemarituzumab In Comb With Chemo: Median Overall Survival 5.7 Months Longer Benzinga

09:01AM EDT Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers PR Newswire

Jun 1, 2021

07:01PM EDT Amgen to Webcast Investor Meeting at ASCO 2021 PR Newswire

09:02AM EDT Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders Benzinga

04:01AM EDT Amgen And Kyowa Kirin To Jointly Develop And Commercialize KHK4083 RTTNews

04:00AM EDT Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase PR Newswire

May 28, 2021

05:00PM EDT Amgen To Present At The 2021 Jefferies Healthcare Conference PR Newswire

document.getElementById("j4Wf0d").onerror = function(){this.style.display='none';}; .dark-mode .rCq41Q{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .rCq41Q{ color: #333333; background-color: white; border: 2px solid #333333; }AMGNAmgen Incstock NASDAQ

AMGN
Amgen Inc
stock NASDAQ